Effect of Tocilizumab on Bone Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Endocrine Connections · 12.11.2026
DOI: 10.1530/ec-26-0503 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrine Connections, online erschienen am 12.11.2026. Verfasst von Feixue Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The Fi…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tocilizumab (TCZ), an interleukin-6 receptor inhibitor for rheumatoid arthritis (RA), may benefit bone metabolism. This meta-analysis aimed to synthesize the effects of TCZ on bone turnover markers (BTMs) and bone mineral density (BMD).
Methods
Cochrane Library, Embase, PubMed, Scopus, and Web of Science were searched from inception to 23 February 2025. Randomized controlled trials and observational studies comparing TCZ with controls and reporting BTMs or BMD were included. Pooled mean differences (MDs) or standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated.
Results
Eight studies involving 1,221 participants were included. TCZ significantly reduced C-terminal telopeptide of type I collagen (CTX-I) (MD = -0.05, 95% CI [-0.08, -0.02], P = 0.001; I2 = 0%) and carboxyterminal telopeptide of type I collagen (ICTP) (MD = -7.19, 95% CI [-12.39, -1.99], P = 0.007; I2 = 97%), and increased procollagen type I N-terminal propeptide (PINP) (SMD = 0.21, 95% CI [0.08, 0.34], P = 0.001; I2 = 0%). The overall effect on osteocalcin (OC) was not significant, whereas RCT subgroup analysis showed a significant increase (MD = 3.83, 95% CI [1.12, 6.54], P = 0.006). No significant improvement in femoral neck BMD or lumbar spine BMD was observed.
Conclusions
TCZ may improve bone metabolism in RA by suppressing bone resorption and promoting bone formation. However, these biochemical changes did not translate into measurable increases in BMD during follow-up. Further long-term studies are warranted to clarify effects on BMD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Affiliated Hospital of China Medical University , Shenyang, Liaoni…
ORCID-Profile: Feixue Jiang, Yushu Li
Zitieren
APA
Jiang, F., Tang, S., Cui, Z., Chen, D., Shan, Z., Teng, W., & Li, Y. (2026). Effect of Tocilizumab on Bone Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Endocrine Connections. https://doi.org/10.1530/ec-26-0503
Vancouver
Jiang F, Tang S, Cui Z, Chen D, Shan Z, Teng W, et al. Effect of Tocilizumab on Bone Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Endocrine Connections. 2026. doi:10.1530/ec-26-0503
BibTeX
@article{Jiang2026,
author = {Jiang, Feixue and Tang, Siqi and Cui, Zhipeng and Chen, Deshi and Shan, Zhongyan and Teng, Weiping and Li, Yushu},
title = {Effect of Tocilizumab on Bone Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis},
journal = {Endocrine Connections},
year = {2026},
doi = {10.1530/ec-26-0503}
}
EUVIMED